Krystal Biotech, Inc. (KRYS)
KRYSNASDAQ-GSBiotechnology: Biological Products (No Diagnostic Substances)
$306.50
+9.06 (+3.05%) today
Closed, Nov 9, 4:00 PM ET
- Market cap
- $8.98bn
- P/E
- 41.6
- EPS, last 4 quarters
- $7.37
- Dividend yield
- –
- Day range
- –
- 52-week range
- $192.52 to $382.54
- Average volume
- 296.6k
- Previous close
- $297.44
Analysts
7 coveringBuy6 buy, 1 hold, 0 sell
Targets a year out average $393.17, +28.3% from here
Earnings
next estimate $2.13Next report
Dec 2025
+4.9%
Mar 2026
+26.2%
Jun 2026
+5.3%
Sep 2026
+11.4%
estimate reported, and the surprise
Financials
| Quarter | Dec 2025 | Mar 2026 | Jun 2026 | Sep 2026 |
|---|---|---|---|---|
| Revenue | $107.11m | $116.36m | $119.22m | $127.34m |
| Gross profit | $100.51m | $110.03m | $112.78m | $119.78m |
| Operating income | $44.27m | $53.69m | $58.42m | $71.15m |
| Net income | $51.40m | $55.93m | $54.77m | $63.07m |
Last four quarters: revenue $470.02m, margin 47.9%, free cash flow $310.08m
News
8 latest- Krystal's Q3 Profit Declines As Clinical Portfolio Advances; Stock Dips By Over 12% RTTNews · Nov 2, 2026
- Krystal Biotech (KRYS) Q3 2026 Earnings Call TranscriptThe Motley Fool · Nov 2, 2026
- Krystal Biotech Q3 Earnings Call HighlightsMarketBeat · Nov 2, 2026
- Krystal Biotech, Inc. (KRYS) Surpasses Q3 Earnings and Revenue EstimatesZacks · Nov 2, 2026
- Krystal Biotech, Inc. Q3 Profit Retreats RTTNews · Nov 2, 2026
- Amgen (AMGN) Reports Next Week: Wall Street Expects Earnings GrowthZacks · Oct 27, 2026
- Analysts Estimate Krystal Biotech, Inc. (KRYS) to Report a Decline in Earnings: What to Look Out forZacks · Oct 26, 2026
- Weekly Buzz: RHHBY, TEVA Win FDA Nod; MLAB, GSK Cut Jobs; AZN, VIR Deals; KRYS, ABBV Report Data RTTNews · Oct 16, 2026
The company
Krystal Biotech, Inc. (NASDAQ: KRYS) is a fully integrated, commercial-stage, global biotechnology company focused on the discovery, development and commercialization of genetic medicines to treat diseases with high unmet medical needs. VYJUVEK, the Company's first commercial product, is the first-ever redosable gene therapy and the first genetic medicine approved in the United States, Europe, and Japan for the treatment of dystrophic epidermolysis bullosa. The Company is rapidly advancing a robust preclinical and clinical pipeline of investigational genetic medicines. Krystal Biotech is headquartered in Pittsburgh, Pennsylvania.
- Sector
- Health Care
- Industry
- Biotechnology: Biological Products (No Diagnostic Substances)
- Exchange
- NASDAQ-GS
- Region
- North America
- Website
- krystalbio.com
Often looked at with it
Figures from Yahoo, Nasdaq (Zacks consensus) and Lighter. Stocks can be minutes behind. Nothing here is advice.